PDF(Pubmed)
Abstract：
UNASSIGNED: Pancreatic ductal adenocarcinoma (PDAC) is in urgent need of a second-line or later-line treatment strategy. We aimed to analyze the efficacy and safety of additional anlotinib, specifically anlotinib in combination with immunotherapy, in patients with PDAC who have failed first-line therapy.
UNASSIGNED: Patients with pathological diagnosis of PDAC were additionally treated with anlotinib, and some patients were treated with anti-PD-1 agents at the same time, which could be retrospectively analyzed. The efficacy and safety of additional anlotinib were evaluated.
UNASSIGNED: A total of 23 patients were included. In patients treated with additional anlotinib, the overall median progression-free survival (PFS) was 1.8 months and the median overall survival (OS) was 6.3 months, regardless of anti-PD-1 agents. Among patients receiving additional anlotinib in combination with anti-PD-1 agents, median PFS and OS were 1.8 and 6.5 months, respectively. Adverse events (AEs) were observed in 16 patients (69.6%). In patients treated with additional anlotinib, the majority of AEs were grade 1-3. Univariate analysis revealed that patients with baseline red blood cell distribution width (RDW) <14% treated with additional anlotinib plus anti-PD-1 agents had significantly longer OS than patients with baseline RDW ≥14% (p = 0.025). Patients with additional anlotinib plus anti-PD-1 agents as second-line therapy had a longer OS than those treated as later-line therapy (p = 0.012). Multivariate analysis showed that baseline RDW was the only independent risk factor for OS (p = 0.042).
UNASSIGNED: The combination of anlotinib and immunotherapy represents an effective add-on therapy with tolerable AEs as second- or later-line therapy in patients with PDAC, particularly in patients with baseline RDW <14%.
UNASSIGNED: Patients with pathological diagnosis of PDAC were additionally treated with anlotinib, and some patients were treated with anti-PD-1 agents at the same time, which could be retrospectively analyzed. The efficacy and safety of additional anlotinib were evaluated.
UNASSIGNED: A total of 23 patients were included. In patients treated with additional anlotinib, the overall median progression-free survival (PFS) was 1.8 months and the median overall survival (OS) was 6.3 months, regardless of anti-PD-1 agents. Among patients receiving additional anlotinib in combination with anti-PD-1 agents, median PFS and OS were 1.8 and 6.5 months, respectively. Adverse events (AEs) were observed in 16 patients (69.6%). In patients treated with additional anlotinib, the majority of AEs were grade 1-3. Univariate analysis revealed that patients with baseline red blood cell distribution width (RDW) <14% treated with additional anlotinib plus anti-PD-1 agents had significantly longer OS than patients with baseline RDW ≥14% (p = 0.025). Patients with additional anlotinib plus anti-PD-1 agents as second-line therapy had a longer OS than those treated as later-line therapy (p = 0.012). Multivariate analysis showed that baseline RDW was the only independent risk factor for OS (p = 0.042).
UNASSIGNED: The combination of anlotinib and immunotherapy represents an effective add-on therapy with tolerable AEs as second- or later-line therapy in patients with PDAC, particularly in patients with baseline RDW <14%.
摘要：
■胰腺导管腺癌（PDAC）迫切需要二线或后期治疗策略。我们旨在分析额外安洛替尼的疗效和安全性，特别是安洛替尼与免疫治疗联合使用，一线治疗失败的PDAC患者。
■病理诊断为PDAC的患者接受安洛替尼治疗，一些患者同时接受抗PD-1药物治疗，可以进行回顾性分析。评估额外安洛替尼的疗效和安全性。
■共纳入23例患者。在接受额外安洛替尼治疗的患者中，中位无进展生存期(PFS)为1.8个月,中位总生存期(OS)为6.3个月,无论抗PD-1药物。在接受额外安洛替尼与抗PD-1药物联合治疗的患者中，中位PFS和OS分别为1.8和6.5个月,分别。16例患者（69.6%）发生不良事件。在接受额外安洛替尼治疗的患者中，大多数AE为1-3级。单变量分析显示，基线红细胞分布宽度（RDW）<14％的患者接受额外的安洛替尼联合抗PD-1药物治疗，其OS明显长于基线RDW≥14％的患者（p=0.025）。使用额外的安洛替尼联合抗PD-1药物作为二线治疗的患者比作为后期治疗的患者具有更长的OS(p=0.012)。多因素分析显示，基线RDW是OS的唯一独立危险因素（p=0.042）。
■安洛替尼和免疫疗法的组合是PDAC患者的一种有效的附加疗法，具有可耐受的不良事件，可作为二线或后期治疗，特别是在基线RDW<14%的患者中。
■病理诊断为PDAC的患者接受安洛替尼治疗，一些患者同时接受抗PD-1药物治疗，可以进行回顾性分析。评估额外安洛替尼的疗效和安全性。
■共纳入23例患者。在接受额外安洛替尼治疗的患者中，中位无进展生存期(PFS)为1.8个月,中位总生存期(OS)为6.3个月,无论抗PD-1药物。在接受额外安洛替尼与抗PD-1药物联合治疗的患者中，中位PFS和OS分别为1.8和6.5个月,分别。16例患者（69.6%）发生不良事件。在接受额外安洛替尼治疗的患者中，大多数AE为1-3级。单变量分析显示，基线红细胞分布宽度（RDW）<14％的患者接受额外的安洛替尼联合抗PD-1药物治疗，其OS明显长于基线RDW≥14％的患者（p=0.025）。使用额外的安洛替尼联合抗PD-1药物作为二线治疗的患者比作为后期治疗的患者具有更长的OS(p=0.012)。多因素分析显示，基线RDW是OS的唯一独立危险因素（p=0.042）。
■安洛替尼和免疫疗法的组合是PDAC患者的一种有效的附加疗法，具有可耐受的不良事件，可作为二线或后期治疗，特别是在基线RDW<14%的患者中。
